Radiotherapy-associated furin expression and tumor invasiveness in recurrent laryngeal cancer

Anticancer Research

Volumn 36, Issue 10, 2016, Pages 5117-5125

  Lee, Myungjin ^a   Ryu, Chang Hwan ^b   Chang, Hyo Won ^a   Kim, Gui Chul ^a   Kim, Seong Who ^a   Kim, Sang Yoon ^a,c  

^a University of Ulsan College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Furin; Invasion; Laryngeal cancer; MMP 2; MT1 MMP; Radiotherapy

Indexed keywords

FURIN; GELATINASE A; MATRIX METALLOPROTEINASE 14; SERINE PROTEINASE INHIBITOR; FURIN PROTEIN, HUMAN; MATRIX METALLOPROTEINASE;

ADVERSE OUTCOME; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IONIZING RADIATION; LARYNGEAL CANCER CELL LINE; LARYNGECTOMY; LARYNX CARCINOMA; MULTIMODALITY CANCER THERAPY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; TISSUE MICROARRAY; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; LARYNGEAL NEOPLASMS; MALE; METABOLISM; NUDE MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FURIN; HUMANS; LARYNGEAL NEOPLASMS; MALE; MATRIX METALLOPROTEINASES; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL;

EID: 84991781106     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: 10.21873/anticanres.11081     Document Type: Article

References (32)

1. Argiris A, Karamouzis MV, Raben D and Ferris R: Head and neck cancer. Lancet 371: 1695-1709, 2008.
2. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N and Fu KK; Radiation Therapy Oncology Group 9501/Intergroup: Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350: 1937-1944, 2004.
3. The Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685-1690, 1991.
4. Gilbert H and Kagan AR: Recurrence patterns in squamous cell carcinoma of the oral cavity, pharynx, and larynx. J Surg Oncol 6: 357-380, 1974.
5. Sacco AG and Cohen EE: Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33: 3305-3313, 2015.
6. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N and Hitt R: Platinumbased chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127, 2008.
7. Argiris A, Karamouzis MV, Gooding WE, Branstetter BF, Zhong S, Raez LE, Savvides P and Romkes M: Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 29: 1140-1145, 2011.
8. Lee JC, Lee WH, Min YJ, Cha HJ, Han MW, Chang HW, Kim SA, Choi SH, Kim SW and Kim SY: Development of TRAIL resistance by radiation-induced hypermethylation of DR4 CpG island in recurrent laryngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 88: 1203-1211, 2014.
9. Seidah NG and Prat A: The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov 11: 367-383, 2012.
10. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, Cherel G, Calvo F, Seidah NG and Khatib AM: Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. J Clin Invest 118: 352-363, 2008.
11. Couture F, Kwiatkowska A, Dory YL and Day R: Therapeutic uses of furin and its inhibitors: a patent review. Expert Opin Ther Pat 25: 379-396, 2015.
12. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA and Klein-Szanto AJ: Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 31: 224-232, 2001.
13. Bassi DE, Mahloogi H, Lopez De Cicco R and Klein-Szanto A: Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 162: 439-447, 2003.
14. Bassi DE, Fu J, Lopez de Cicco R and Klein-Szanto AJ: Proprotein convertases: master switches in the regulation of tumor growth and progression. Mol Carcinog 44: 151-161, 2005.
15. Chien MH, Lin CW, Cheng CW, Wen YC and Yang SF: Matrix metalloproteinase-2 as a target or head and neck cancer therapy. Expert Opin Ther Targets 17: 203-216, 2013.
16. Kessenbrock K, Plaks V and Werb Z. Matrix Metalloproteinases: Regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
17. Page-McCaw A, Ewald AJ and Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8: 221-233, 2007.
18. Kim SY, Chu KC, Lee HR, Lee KS and Carey TE: Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol (Stockh) 117: 775-784, 1997.
19. Lee JC, Lee WH, Min YJ, Cha HJ, Han MW, Chang HW, Kim SA, Choi SH, Kim SW and Kim SY: Development of TRAIL resistance by radiation-induced hypermethylation of dr4 cpg island in recurrent laryngeal squamous cell carcinoma. Int. J Radiat Oncol 88: 1203-1211, 2014.
20. Polyak K and Weinberg RA: Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273, 2009.
21. Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelialmesenchymal transitions in development and disease. Cell 139: 871-890, 2009.
22. Nieto MA: The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu Rev Cell Dev Biol 27: 347-376, 2011.
23. Klein T and Bischoff R: Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41: 271-290, 2011.
24. Page RE, Klein-Szanto AJ, Litwin S, Nicolas E, Al-Jumaily R, Alexander P, Godwin AK, Ross EA, Schilder RJ and Bassi DE: Increased expression of the pro-protein convertase furin predicts decreased survival in ovarian cancer. Cell Oncol 29: 289-299, 2007.
25. Roy R, Yang J and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 27: 5287-5297, 2009.
26. Patel BP, Shah SV, Shukla SN, Shah PM and Patel PS: Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 29: 564-572, 2007.
27. Chung CH: Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500, 2004.
28. Bogusiewicz M, Stryjecka-Zimmer M, Szymanski M, Rechberger T and Golabek W: Activity of matrix metalloproteinases-2 and-9 in advanced laryngeal cancer. Otolaryngol Head Neck Surg 128: 132-136, 2003.
29. Xie M, Sun Y and Li Y: Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 114: 2243-2248, 2004.
30. Wiegand S, Dünne AA, Müller HH, Mandic R, Barth P, Davis RK and Werner JA: Meta-analysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 104: 94-100, 2005.
31. Coppola JM, Bhojani MS, Ross BD and Rehemtulla A: A smallmolecule furin inhibitor inhibits cancer cell motility and invasiveness. Neoplasia 10: 363-370, 2008.
32. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G and Klein-Szanto AJ: Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 8: 1740-1746, 2002.